Profile of prescriptions of drugs for Covid-19 at the General Hospital of Unimed, Belém, Pará, Amazon
DOI:
https://doi.org/10.33448/rsd-v10i15.22698Keywords:
Covid-19; SARS-CoV-2; Hospital Pharmacy; Pharmacy Services; Pharmaceutical care.Abstract
Objective: To investigate the clinical profile and prescription of drugs used in the treatment of Covid-19 in patients admitted to the Unimed General Hospital in Belém, Pará, Amazon. Method: A cross-sectional, retrospective, exploratory, descriptive and analytical study on the use of medications applied to the treatment of Covid-19, with the period between April and October 2020 as a time frame. Results: It was observed that patients hospitalized with Covid-19, were predominantly diagnosed by the RT-PCR method, and most of them were aged ≥60 years, with one or more comorbidities. They presented leukocytosis, neutrophilia, lymphopenia, increased C-reactive protein and D-dimer CRP. The average hospital stay was 12 days. Elderly male patients showed greater vulnerability. The chance of death was very expressive in patients who required orotracheal intubation. A total of 3,398 potential interactions were found, revealing a higher absolute frequency of interactions of the pharmacodynamic type (n=2,233) compared to pharmacokinetic ones (n=1,165). Potential interactions were categorized, accounting for a total of 3,379; being (n=2.181) moderate, (n=734) severe and (n=464) mild. Conclusion: There was a proportional lower occurrence of deaths among patients who used dexamethasone compared to those who did not use it. There was a higher occurrence of deaths among users of enoxaparin and heparin compared to patients who did not use them. The medications oseltamivir, hydroxychloroquine and azithromycin also presented a risk association for the outcome of death.
References
Academy of Managed Care Pharmacy (AMCP). (2019). Drug Utilization Review. Drug Utilization Review. Drug Utilization Review | AMCP.org
Acrítica (Redação). (2021). Diretor da Unimed detalha projeto que reduz consumo de medicamentos usados por pacientes internados com covid. Diretor da Unimed detalha projeto que reduz consumo de medicamentos usados por pacientes internados com Covid - A Crítica de Campo Grande (acritica.net)
Alencar, J., Moreira, C. L., Müller, A. D., Chaves, C. E., Fukuhara, M. A., da Silva, E. A., Miyamoto, M., Pinto, V. B., Bueno, C. G., Lazar Neto, F., Gomez Gomez, L. M., Menezes, M., Marchini, J., Marino, L. O., Brandão Neto, R. A., Souza, H. P., & Covid Register Group (2021). Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 72(11): e736–e741. https://doi.org/10.1093/cid/ciaa1443
American College of Radiology (ACR). (2020). ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected Covid-19 infection. American College of Radiology. March 11, 2020. Home | American College of Radiology (acr.org)
Andreania, J., Le Bideaua, M., Duflota, I., Jardota, P., Rollanda, C., Boxbergera, M. et al., (2020). In vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows 1 synergistic effect 2. Lung. 21:22. doi: 10.1016 / j.micpath.2020.104228.
Atallah, B., Sadik, Z.G., Salem, N., El Nekidy, W. S., Almahmeed, W., Park, W. M., Cherfan, A., Hamed, F. & Mallat, J. (2021). The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill Covid-19 patients. Anaesthesia. 76(3):327-335. https://doi.org/10.1111/anae.15300.
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W.L., Ademuyiwa, A.O., & Omilabu, S. (2021). Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos. medRxiv 2021.01.05.21249131; doi: https://doi.org/10.1101/2021.01.05.21249131
Belém. Secretaria Municipal de Saúde. Prefeitura Municipal de Belém. (2021). Doença pelo novo coronavírus: Covid-19. Boletim epidemiológico de 03 de janeiro de 2021. Belém. Pará. http://ww4.belem.pa.gov.br/wp-content/uploads/2021/01/31-Anexo-boletim-epidemiol%c3%93gico_covid19_bel%c3%89m_03_01_2021_base_31_12_2020.pdf.
Billett, H.H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R., Lo, Y., Rahman, S., Gonzalez-Lugo, J.D., Kushnir, M., Barouqa, M., Golestaneh, L. & Bellin, E. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and haemostasis. 120(12):1691-1699. https://doi.org/10.1055/s-0040-1720978.
Borba, M., Val, F., Sampaio, V. S., Alexandre, M., Melo, G. C., Brito, M., Mourão, M., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M., Hajjar, L. A., Pinto, R. C., Balieiro, A., Pacheco, A., Santos, J., Jr, Naveca, F. G., Xavier, M. S., Siqueira, A. M., Schwarzbold, A., Croda, J., CloroCovid-19 Team. (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA network open. 3(4):e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857
Brasil. (2020). Ministério da Saúde. Painel coronavírus: Coronavírus Brasil (saude.gov.br)
Brasil. (2020). Diretrizes para diagnóstico e tratamento da Covid-19: Versão 2, de 08 de abril de 2020. Ministério da Saúde. Brasília. Distrito Federal. https://saude.rs.gov.br/upload/arquivos/202004/14140600-2-ms-diretrizes-covid-v2-9-4.pdf.
Brasil. (2020). Conselho Nacional de saúde (CNS). Recomendação nº 042, de 22 de maio de 2020.Recomenda a suspensão imediata das Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes com diagnóstico da COVID-19, como ação de enfrentamento relacionada à pandemia do novo coronavírus. http://conselho.saude.gov.br/recomendacoes-cns/1193-recomendacao-n-042-de-22-de-maio-de-2020.
Brasil. (2020). Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes com diagnóstico da Covid-19. Nota Informativa n° 17/2020. SE/GAB/SE/MS. Ministério da Saúde. http://www.consultaesic.cgu.gov.br/busca/dados/Lists/Pedido/Attachments/1527690/REsposta_recurso_1_131 580_nota%20informativa%20n%2017_2020-gab_se_ms.pdf.
Brasil. (2021). Ministério da Saúde. Agência Nacional de Vigilância Sanitária. NT Rendesivir para tratamento de paciência com Covid-19. Departamento de Gestão e Incorporação de Tecnologias e Inovação em Saúde. 20210615_Relatorio_rendesivir_covid19_CP_54.pdf (conitec.gov.br)
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 178:104787. https://doi.org/10.1016/j.antiviral.2020.104787
Casanova, O., Penteado, S., & Linartevichi, V. (2019). Análise de interações medicamentosas em Unidade de Terapia Intensiva em um hospital no Sul do Brasil. Fag Journal of Health (FJH), 1(1):81-88. https://doi.org/10.35984/fjh.v1i1.6.
Castillo, P., Richardson, M.A., Rodríguez-Mateos, M., Jordan-Iborra, C., Brew, J., Carmona-Torreb, F., Giraldez, M., Laso, E., Gabaldon-Figueira, J.C., Dobano, C., Moncunilla, G., Yuste, J.R., Del Pozo J.L.N., Rabinovicha, R., Schoning, V., Hammann, F., Reinab, G., Sadaba, B. & Fernandez-Alonso, M. (2021). The effect of early treatment with ivermectin on viral load, symptoms, and humoral response in patients with non-severe Covid-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 32:100720. DOI: https://doi.org/10.1016/j.eclinm.2020.100720.
Castro, C. G. S. O. (Coord.). (2000). Estudos de utilização de medicamentos: noções básicas [online]. Rio de Janeiro: Editora FIOCRUZ, 2000. 92p. ISBN 85-85676-89-2. ARCA: Estudos de utilização de medicamentos: noções básicas (fiocruz.br)
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., Junqueira, D., de Barros E Silva, P., Tramujas, L., Abreu-Silva, E. O., Laranjeira, L. N., Soares, A. T., Echenique, L. S., Pereira, A. J., Freitas, F., Gebara, O., & Coalition Covid-19 Brazil I Investigators. (2020). Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. The New England journal of medicine. 383(21):2041-2052. https://doi.org/10.1056/NEJMoa2019014.
Centro Nacional de Informações sobre Biotecnologia (2021). Resumo do composto PubChem para CID 447043, azitromicina. https://pubchem.ncbi.nlm.nih.gov/compound/Azithromycin.
Centro Nacional de Informações sobre Biotecnologia (2021). Resumo do composto PubChem para CID 3652, hidroxicloroquina. Hydroxychloroquine | C18H26ClN3O - PubChem (nih.gov)
Centro Nacional de Informações sobre Biotecnologia (2021). Resumo do composto PubChem para CID 6321424, Ivermectina. https://pubchem.ncbi.nlm.nih.gov/compound/Ivermectin.
Chaccoura, C., Casellasa, A., Matteo, A.B., Pineda, I., Fernandez-Montero, A., Ruiz-Cox, M. J., Loman, N., Bogaert, D., & O'Grady, J. (2020). Co-infections: potentially lethal and unexplored in Covid-19. The Lancet. Microbe. 1(1):e11. https://doi.org/10.1016/S2666-5247(20)30009-4.
Falavigna, M., Colpani, V., Stein, C., Azevedo, L., Bagattini, A. M., Brito, G. V., Chatkin, J. M., Cimerman, S., Corradi, M., Cunha, C., Medeiros, F. C., Oliveira Junior, H. A., Fritscher, L. G., Gazzana, M. B., Gräf, D. D., Marra, L. P., Matuoka, J. Y., Nunes, M. S., Pachito, D. V., Pagano, C., & Dal-Pizzol, F. (2020). Guidelines for the pharmacological treatment of COVID-19. The taskforce/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases, and the Brazilian Society of Pulmonology and Tisiology. Diretrizes para o tratamento farmacológico da Covid-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Revista Brasileira de Terapia Intensiva. 32(2):166-196. https://doi.org/10.5935/0103-507x.20200039.
Fang, X., Li, S., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., & Ma, X. (2020). Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging. 12(13):12493-12503. https://doi.org/10.18632/aging.103579.
Furtado, R., Berwanger, O., Fonseca, H. A., Corrêa, T. D., Ferraz, L. R., Lapa, M. G., Zampieri, F. G., Veiga, V. C., Azevedo, L., Rosa, R. G., Lopes, R. D., Avezum, A., Manoel, A., Piza, F., Martins, P. A., Lisboa, T. C., Pereira, A. J., Olivato, G. B., Dantas, V., Milan, E. P., & Coalition Covid-19 Brazil II Investigators. (2020). Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe Covid-19 in Brazil (Coalition II): a randomised clinical trial. Lancet (London, England). 396(10256):959-967. https://doi.org/10.1016/S0140-6736(20)31862-6.
Garcia, P. J., Mundaca, H., Ugarte-Gil, C., Leon, P., Malaga, G., Chaccour, C., & Carcamo, C. P. (2021). Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early Covid-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials. 22(1):262. https://doi.org/10.1186/s13063-021-05236-2.
Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 56(1):105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
Gérard, A., Romani, S., Fresse, A., Viard, D., Parassol, N., Granvuillemin, A., Chouchana, L., Rocher, F., Drici, M. D., & French Network of Pharmacovigilance Centers. (2020). "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir, and chloroquine in Covid-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 75(4):371-379. https://doi.org/10.1016/j.therap.2020.05.002.
Goodnough, R., & Canseco, K. (2021). Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic. Clinical toxicology (Philadelphia, Pa.). 59(1):69. https://doi.org/10.1080/15563650.2020.1758327.
Güçlü, E., Kocayiğit, H., Okan, H. D., Erkorkmaz, U., Yürümez, Y., Yaylacı, S., Koroglu, M., Uzun, C., & Karabay, O. (2020). Effect of COVID-19 on platelet count and its indices. Revista da Associação Medica Brasileira. 66(8):1122-1127. https://doi.org/10.1590/1806-9282.66.8.1122.
Hani, C., Trieu, N. H., Saab, I., Dangeard, S., Bennani, S., Chassagnon, G., & Revel, M. P. (2020). Covid-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagnostic and Interventional Imaging. 101(5):263-268. https://doi.org/10.1016/j.diii.2020.03.014.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Huttner, B., Catho, G., Pano-Pardo, J. R., Pulcini, C. & Schouten, J. (2020). Covid-19: don’t neglect antimicrobial stewardship principles! Clinical Microbiology and Infection. 26(7):808-810. DOI: https://doi.org/10.1016/j.cmi.2020.04.024.
Jeronimo, C., Farias, M., Val, F., Sampaio, V. S., Alexandre, M., Melo, G. C., Safe, I. P., Borba, M., Netto, R., Maciel, A., Neto, J., Oliveira, L. B., Figueiredo, E., Oliveira Dinelly, K. M., de Almeida Rodrigues, M. G., Brito, M., Mourão, M., Pivoto João, G. A., Hajjar, L. A., Bassat, Q., & Metcovid Team. (2021). Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (Covid-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clinical infectious diseases: an official publication of the Infectious. Diseases Society of America. 72(9): e373–e381. https://doi.org/10.1093/cid/ciaa1177.
Kalil A. C. (2020). Treating Covid-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 323(19):1897-1898. https://doi.org/10.1001/jama.2020.4742.
Lemaitre F, Solas C, Gregoire, M., et al. (2020). Potenciais interações medicamentosas associadas aos medicamentos atualmente propostos para o tratamento com COVID-19 em pacientes recebendo outros tratamentos. Fundam. Clin. Pharmacol. 34:530-547. https://doi.org/10.1111/fcp.12586.
Li, L. Q., Huang, T., Wang, Y. Q., Wang, Z. P., Liang, Y., Huang, T. B., Zhang, H. Y., Sun, W., & Wang, Y. (2020). Covid-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. Journal of Medical Virology. 92(6):577-583. https://doi.org/10.1002/jmv.25757.
Lima, J.V.O., Cavalcante, G.L., Braga, N.S.M., da Silva, A.R., da Silva, T.M., Gomes, B.P., et. al. (2020). Potential risk of investigated drugs for the treatment of COVID-19: drugs interactions. Rev Pre Infec e Saúde. 6:10829. https://revistas.ufpi.br/index.php/nupcis/article/view/10829 DOI: https://doi.org/10.26694/repis.v6i0.10829.
Liu, Q., Fang, X., Tian, L. et al. (2020). The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world date from three hospitals in Wuhan. medRxiv. 2020.04.11.20056523; doi: https://doi.org/10.1101/2020.04.11.20056523
Mangia, C., Russo, A., Civitelli, S., & Gianicolo, E. (2020). Differenze sesso/genere nella letalità Covid-19: cosa dicono e non dicono i dati [Sex/gender differences in COVID-19 lethality: what the data say, and do not say]. Epidemiologia e prevenzione. 44(5-6 Suppl 2):400-406. https://doi.org/10.19191/EP20.5-6.S2.145.
Martín, U., Bacigalupe, A., & Jiménez Carrillo, M. (2021). Covid-19 y género: certezas e incertidumbres en la monitori-zación de la pandemia [Covid-19 and gender: certainties and uncertainties in monitoring the pandemic.]. Revista Espanola de Salud Publica. 95:e202104066.
Mattioli, M., Benfaremo, D., Mancini, M., Mucci, L., Mainquà, P., Polenta, A., Baldini, P. M., Fulgenzi, F., Dennetta, D., Bedetta, S., Gasperoni, L., Caraffa, A. & Frausini, G. (2021). Safety of intermediate dose of low molecular weight heparin in Covid-19 patients. Journal of thrombosis and thrombolysis. 51(2):286-292. https://doi.org/10.1007/s11239-020-02243-z.
Million, M., Lagier, J. C., Gautret, P., Colson, P., Fournier, P. E., Amrane, S., Hocquart, M., Mailhe, M., Esteves-Vieira, V., Doudier, B., Aubry, C., Correard, F., Giraud-Gatineau, A., Roussel, Y., Berenger, C., Cassir, N., Seng, P., Zandotti, C., Dhiver, C., Ravaux, I., & Raoult, D. (2020). Early treatment of Covid-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel medicine and infectious disease. 35:101738. https://doi.org/10.1016/j.tmaid.2020.101738.
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020). No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe Covid-19 infection. Medecine et maladies infectieuses. 50(4):384. https://doi.org/10.1016/j.medmal.2020.03.006.
Momekov, G. & Momekova D. (2020) Ivermectina como um tratamento potencial COVID-19 do ponto de vista farmacocinético: os níveis antivirais não são provavelmente atingíveis com regimes de dosagem conhecidos, Biotecnologia e Equipamento Biotecnológico. 34(1):469-474. DOI: 10.1080 /13102818.2020.1775118.
Monteiro, D. V. D. S., Dos Santos, D. D. L., Nunes, E., Brabo, J. S., & da Silva, M. C. R. (2021). O uso de anticoagulantes na Covid-19. Revista Multidisciplinar Em Saúde. 2(2):05. https://doi.org/10.51161/rems/944
Naksuk, N., Lazar, S., & Peeraphatdit, T. B. (2020). Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. European heart journal. Acute cardiovascular care. 9(3):215-221. https://doi.org/10.1177/2048872620922784.
Noblat, A.C.B., et al. (2011). Prevalência de admissão hospitalar por reação adversa a medicamentos em Salvador, BA. Revista da Associação Médica Brasileira. 57(1):42-45. https://doi.org/10.1590/S0104-42302011000100014.
Noronha, K.V. M. S et al. (2020). Pandemia por Covid-19 no Brasil: análise da demanda e da oferta de leitos hospitalares e equipamentos de ventilação assistida segundo diferentes cenários. Cadernos de Saúde Pública. 36(6):e00115320. https://doi.org/10.1590/0102-311X00115320.
Organização Panamericana de Saúde (OPAS). (2020). Brasil Covid-19. https://www.paho.org/pt/covid19.
Papamanoli, A., Yoo, J., Grewal, P., Predun, W., Hotelling, J., Jacob, R., Mojahedi, A., Skopicki, H. A., Mansour, M., Marcos, L. A., & Kalogeropoulos, A. P. (2021). High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. European journal of clinical investigation. 51(2):e13458. https://doi.org/10.1111/eci.13458.
Pará. Secretaria Executiva de Saúde do Estado do Pará. Painel Covid-19. 2020. https://www.covid-19.pa.gov.br/public/dashboard/41777953-93bf-4a46-b9c2-3cf4ccefb3c9
Passos, M. M. B., Castoldi, V. M. & Soler, O. (2021). O papel do farmacêutico na pandemia de Covid-19: Revisão integrativa. Research, Society and Development. 10(6):e27110615809. ISSN 2525-3409. DOI: http://dx.doi.org/10.33448/rsd-v10i6.15809.
Principle Trial Collaborative Group (2021). Azithromycin for community treatment of suspected Covid-19 in people at increased risk of an adverse clinical course in the UK (Principle): a randomised, controlled, open-label, adaptive platform trial. Lancet (London, England). 397(10279):1063-1074. https://doi.org/10.1016/S0140-6736(21)00461-X.
Ranjbar, K., Moghadami, M., Mirahmadizadeh, A., et al. (2021). Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized Covid-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 21:337 https://doi.org/10.1186/s12879-021-06045-3
Recovery Collaborative Group, Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., & Landray, M. J. (2021). Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 384(8):693-704. https://doi.org/10.1056/NEJMoa2021436.
Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., Blog, D. S., Hutton, B., Holtgrave, D. R., & Zucker, H. A. (2020). Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With Covid-19 in New York State. JAMA. 323(24):2493-2502. https://doi.org/10.1001/jama.2020.8630.
Saleh, M., Gabriels, J., Chang, D., Kim, B.S., Mansoor, A., Mahmood, E., et al. (2020). The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol. (6):1-12. http://dx.doi.org/10.8762/BST.2020.07397.
Santos, L., Torriani, M. S., & Barros E. (2013). Medicamentos na Prática da Farmácia Clínica. Artmed Editora. ISBN 8582710011, ISBN 9788582710012. 1117p.
Schrezenmeier, E., & Dörner, T. (2020). Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature reviews. Rheumatology. 16(3):155-166. https://doi.org/10.1038/s41584-020-0372-x.
Shi, Z., & Puyo, C. A. (2020). N-Acetylcysteine to Combat Covid-19: An Evidence Review. Therapeutics and clinical risk management. 16:1047-1055. https://doi.org/10.2147/TCRM.S273700.
Shojaei, A., & Salari, P. (2020). Covid-19 and off label use of drugs: an ethical viewpoint. Daru: Journal of Faculty of Pharmacy (Tehran University of Medical Sciences). 28(2):789-793. https://doi.org/10.1007/s40199-020-00351-y.
Stein, C., Falavigna, M., Pagano, C. G. M., Gräf, D. D., Matuoka, J. Y., Oliveira Jr, H. A., Medeiros, F. C., Brito, G. V., Marra, L. P., Parreira, P. C. L., Bagattini, A. M., Pachito, D. V., Riera, R., & Colpani, V. (2020). Associação hidroxicloroquina/cloroquina e azitromicina para Covid-19. Revisão sistemática rápida. https://oxfordbrazilebm.com/index.php/2020/05/27/oseltamivir-no-tratamento-da-covid-19-revisao-sistematica-rapida/
Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., Demertzis, Z., Hanna, Z., Failla, A., Dagher, C., Chaudhry, Z., Vahia, A., Abreu Lanfranco, O., Ramesh, M., Zervos, M. J., Alangaden, G., Miller, J., & Brar, I. (2020). Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA network open. 3(6): e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270.
Suter, P.M., Domenighetti, G., Schaller, M. D., Laverrière, M. C., Ritz, R. & Perret, C. (1994). N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 105(1):190-194. https://doi.org/10.1378/chest.105.1.190.
Thomas-Rüddel, D., Winning, J., Dickmann, P., Ouart, D., Kortgen, A., Janssens, U., & Bauer, M. (2020). Coronavirus disease 2019 (Covid-19): update für Anästhesisten und Intensivmediziner März 2020 [Coronavirus disease 2019 (Covid-19): update for anesthesiologists and intensivists March 2020]. Der Anaesthesist. 69(4):225-235. https://doi.org/10.1007/s00101-020-00758-x.
Tomazini, B. M., Maia, I. S., Cavalcanti, A. B., Berwanger, O., Rosa, R. G., Veiga, V. C., Avezum, A., Lopes, R. D., Bueno, F. R., Silva, M., Baldassare, F. P., Costa, E., Moura, R., Honorato, M. O., Costa, A. N., Damiani, L. P., Lisboa, T., Kawano-Dourado, L., Zampieri, F. G., Olivato, G. B., & Coalition Covid-19 Brazil III Investigators. (2020). Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and Covid-19: The CoDEX Randomized Clinical Trial. JAMA. 324(13):1307-1316. https://doi.org/10.1001/jama.2020.17021.
Touret, F., Gilles, M., Barral, K., Nougairède, A., Decroly, E., de Lamballerie, X., et al. (2020). In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. bioRxiv. https://doi.org/10.1101/2020.04.03.023846.
Walley, T., & Haycox, A. (1997). Pharmacoeconomics: basic concepts and terminology. British journal of clinical pharmacology. 43(4):343-348. https://doi.org/10.1046/j.1365-2125.1997.00574.x.
Wang, D., Hu, B., Hu, C., et al. (2020). Clinical caracteristics of 138 hospitalized patients with 2019 novel coronavirus - infected pneumonia in Wuhan, China. JAMA. E1-E9. https://doi.org/10.1001/jama.2020.1585.
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 323(11):1061-1069. https://doi.org/10.1001/jama.2020.1585.
Wong, A., McNulty, R., Taylor, D., et al. (2019). O estudo Nacstop: um estudo multicêntrico controlado por agrupamento de cessação precoce da acetilcisteina em overdose de paracetamol. Hepatologia. 69(2):774-784. Doi.org/10.1002/hep.30224.
Wong, S. H., Lui, R. N., & Sung, J. J. (2020). Covid-19 and the digestive system. Journal of gastroenterology and hepatology. 35(5):744-748. https://doi.org/10.1111/jgh.15047.
World Health Organization. (2004). How to investigate the use of medicines by consumers. Department of Essential Drugs and Medicines Policy of World Health Organization and University of Amsterdam. Geneva: WHO/University of Amsterdam. Manual1_HowtoInvestigate.pdf (who.int)
World Health Organization. (2017). Medication Without Harm – Global Patient Safety Challenge on Medication Safety. Geneva: World Health Organization.
Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., Yan, Y. Q., Akdis, C. A., & Gao, Y. D. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 75(7):1730-1741. https://doi.org/10.1111/all.14238.
Zhou, D., Dai, SM, & Tong, Q. (2020). COVID-19: uma recomendação para examinar o efeito da hidroxicloroquina na prevenção da infecção e progressão. The Journal of antimicrobial chemotherapy. 75(7):1667-1670. https://doi.org/10.1093/jac/dkaa114.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020a). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
Zhou, L., Zhang, M., Wang, J., & Gao, J. (2020). Sars-Cov-2: Underestimated damage to nervous system. Travel medicine and infectious disease. 36:101642. https://doi.org/10.1016/j.tmaid.2020.101642.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ivan Pereira da Silva ; Maycon Ruan Lima de Araújo ; José Ronaldo Teixeira de Sousa Junior; Antonio dos Santos Silva; Luana Melo Diogo de Queiroz; Márcia Maria Barros dos Passos; Orenzio Soler
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
